Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 12, 2024

BUY
$338.91 - $506.01 $33,891 - $50,601
100 New
100 $38,000
Q1 2021

Apr 12, 2021

SELL
$268.3 - $380.31 $1.56 Million - $2.21 Million
-5,800 Closed
0 $0
Q4 2020

Jan 19, 2021

BUY
$248.13 - $308.36 $1.44 Million - $1.79 Million
5,800 New
5,800 $1.71 Million
Q3 2020

Oct 09, 2020

SELL
$215.51 - $272.51 $215,510 - $272,510
-1,000 Closed
0 $0
Q2 2020

Jul 10, 2020

BUY
$127.44 - $232.72 $127,440 - $232,720
1,000 New
1,000 $225,000
Q1 2020

Apr 09, 2020

SELL
$108.83 - $165.23 $721,651 - $1.1 Million
-6,631 Closed
0 $0
Q4 2019

Jan 10, 2020

BUY
$106.59 - $164.21 $123,218 - $189,826
1,156 Added 21.11%
6,631 $1.06 Million
Q3 2019

Oct 25, 2019

BUY
$113.31 - $150.51 $620,372 - $824,042
5,475 New
5,475 $623,000
Q2 2019

Jul 24, 2019

SELL
$115.0 - $141.58 $345,000 - $424,740
-3,000 Closed
0 $0
Q1 2019

Apr 17, 2019

BUY
$98.85 - $134.59 $296,550 - $403,770
3,000 New
3,000 $374,000
Q4 2018

Jan 22, 2019

SELL
$63.81 - $109.82 $2.74 Million - $4.72 Million
-43,000 Closed
0 $0
Q3 2018

Oct 29, 2018

BUY
$75.5 - $96.63 $3.25 Million - $4.16 Million
43,000 New
43,000 $3.26 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.9B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Fny Investment Advisers, LLC Portfolio

Follow Fny Investment Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fny Investment Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fny Investment Advisers, LLC with notifications on news.